Healio (5/2, Gramigna) reported, “Clinical data support the effectiveness of ketamine and esketamine for difficult-to-treat depression and major depressive disorder [MDD] with suicidal ideation, according to” a presentation given by Richard C. Shelton, MD, director of the University of Alabama at Birmingham Depression and Suicide Center, at the American Psychiatric Association virtual annual meeting. During the presentation, Dr. Shelton discussed findings from several studies and outlined “limitations and concerns.” (SOURCE: APA Headlines)